Consistent with other studies, including a large meta-analysis, this study indicates no increased risk of ADHD in offspring following prenatal exposure to antidepressants.
This meta-analysis is reassuring regarding risk for malformations in children exposed prenatally to oxcarbazepine; however, we still need more data to fully assess reproductive safety.
Data from a Nordic register-based study observed a significant increase in risk for autism spectrum disorder and intellectual disability in children with prenatal exposure to topiramate.
Treatment with buprenorphine versus methadone during pregnancy is associated with lower risk of preterm birth, low birth weight, small size for gestational age, and NAS.
The largest study to date observes no increase in risk of autism or ADHD in children with prenatal exposure to benzodiazepines.
The use of valproic acid during pregnancy is associated with a significant increase in risk of major malformations and neurodevelopmental disorders. Given these risks, should it be a treatment option for women of childbearing age?
Analyzing data from nearly 150,000 children with prenatal antidepressant exposure in two healthcare databases, a recent study finds no association between prenatal exposure to antidepressants and risk for neurodevelopmental disorders.
Although a small sample, no major malformations were observed in a prospectively followed cohort of women with first trimester exposure to buspirone.
In a cohort of 351 children exposed to second generation antipsychotic during pregnancy, the risk of major congenital malformations did not differ from a comparison group of non-exposed children.
Our data regarding prenatal exposure to BZDs and/or z-drugs and risk of neurodevelopmental outcomes is still sparse.
